EUROPE Winner... JOHN HAWKINS

CEO of All in One Medical United Kingdom

About All in One Medical The quest to eradicate hospital- acquired infections across the world is one step closer thanks to innovative product development by All in One Medical.

In the early 2000’s, DCCL, now trading as All in One Medical, recognised a growing and urgent need to combat the spread of hospital-acquired infections across the world.

This was, and still is a global public health issue. Hospitals in the UK face fines if they fail to meet

Product application

In 2003 All in One Medical patented biocidal protected hospital curtains, and a hook mechanism for quick release to speed up changing of bed bays and eliminate cross contamination of infections.

Multiple teaching hospitals adopted the new designs, costing less than the products they were currently using. This delivered considerable savings to the NHS at the same time.

The company also recognised that patients need safe care whilst in a vulnerable state in hospital. Their products help to protect patients and their families from the risk of cross infection. The typical patient curtain harbours many potentially infectious pathogens such as MRSA, C. diff and VRE. All of these can cross infect patients as they, or their carers, simply pull the curtains for privacy.

The All in One Medical curtains do

not harbour pathogens. The Fantex coating kills them stone dead. Thus an increasing number of top teaching hospitals between the UK and Australia are buying their curtains and window blinds from All in One Medical.

The product range in the health sector has developed further and now extends beyond hospital bed curtains and blinds to soft furnishings, mattress covers and cleaning products.

John Hawkins - A man with

minimum standards of hygiene or if cross infection rates are unacceptably high.

All in One Medical researched and developed uses for the chemical compound known as Fantex, remarkable for its microbial protection properties.

And by applying the chemical to produce a series of biocidal fabrics the results were staggering. With the fabrics attracting, capturing and killing 99.999% of germs, the possibility

of using them to protect patients within hospitals became a reality.

In fact, Fantex is proven to be effective in eradicating known pathogens, including the SARS coronavirus, Norovirus, MRSA and C. diff. It is also highly effective against E. coli, VRE, P. aeruginosa and Candida albicans.

And the beauty of the product is that it offers continued protection throughout its life, continuing antibacterial action even after repeated contamination.

John Hawkins, CEO of All in One Medical, was a senior partner in Accenture, before moving on to All in One Medical 4 years ago.

In his previous roles, he has been a strategic thinker, a visionary, and a manager of change and transformation. It is these qualities that he brings to All in One Medical, spearheading considerable growth of the company.

John is the driving force behind new product development, keen to capitalise on the immense potential that Fantex holds within and beyond the healthcare sector.

And he played an integral role in the key decision to move manufacture from China to its base

Investment

Earlier this year, growth capital investors Beringea invested £3m in DCCL in recognition of the growth prospects for the company, and the work and vision that John has brought to the business.

They recognise that there are a number of opportunities to develop the product range outside of the healthcare sector, which in itself

FINANCE MONTHLY CEO AWARDS 2014

John Hawkins, CEO of All in One Medical 38 www.finance-monthly.com